ZW25 (Zanidatamab) + Palbociclib + Fulvestrant
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2+/HR+ Breast Cancer
Conditions
HER2+/HR+ Breast Cancer
Trial Timeline
Jun 10, 2020 → Jun 30, 2025
NCT ID
NCT04224272About ZW25 (Zanidatamab) + Palbociclib + Fulvestrant
ZW25 (Zanidatamab) + Palbociclib + Fulvestrant is a phase 2 stage product being developed by Jazz Pharmaceuticals for HER2+/HR+ Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04224272. Target conditions include HER2+/HR+ Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04224272 | Phase 2 | Completed |